NCT03485976View on ClinicalTrials.gov

Ixekizumab in the Treatment of Pityriasis Rubra Pilaris (PRP)

PHASE2CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

May 23, 2018

Primary Completion Date

October 14, 2019

Study Completion Date

January 13, 2020

Conditions
Pityriasis Rubra Pilaris
Interventions
DRUG

Ixekizumab

Treatment at the FDA-approved psoriasis dosing

Trial Locations (1)

97239

Oregon Health and Science University, Portland

All Listed Sponsors
collaborator

Eli Lilly and Company

INDUSTRY

lead

Oregon Health and Science University

OTHER

NCT03485976 - Ixekizumab in the Treatment of Pityriasis Rubra Pilaris (PRP) | Biotech Hunter | Biotech Hunter